AltheaDx specializes in advanced diagnostic technologies that focus on personalized medicine, particularly in the fields of oncology and pharmacogenomics. Their flagship products include DecisionDx tests, which utilize gene expression profiling to provide prognostic information for various cancers, such as melanoma and cutaneous squamous cell carcinoma. These tests help clinicians make informed decisions regarding patient management by assessing the likelihood of disease progression and response to treatment. Additionally, AltheaDx offers TissueCypher, a diagnostic tool that aids in the evaluation of Barrett's esophagus, and DecisionDx-UM, which focuses on uveal melanoma. These technologies are supported by scientific evidence and aim to enhance patient outcomes through tailored treatment strategies.

In the realm of pharmacogenomics, AltheaDx's IDgenetix platform stands out as a comprehensive solution that integrates genetic, drug-drug interaction, and lifestyle factors to optimize medication selection for mental health treatment. This advanced pharmacogenomic testing helps clinicians predict how individual patients will respond to specific medications, thereby reducing the reliance on trial-and-error approaches. By identifying metabolic phenotypes and potential interactions, IDgenetix aims to improve treatment efficacy and increase remission rates for patients with mental health conditions. Overall, AltheaDx's innovative technologies are designed to facilitate personalized healthcare and improve clinical decision-making across various medical disciplines.

United States

AltheaDx, Inc. is a commercial stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx).  IDgenetix® is AltheaDx’s PGx product test for depression and anxiety and is supported by a published/peer-reviewed Randomized Controlled Trial that demonstrated clinical utility over standard of care when physicians used the test prior to prescribing a medication.

AltheaDx

Company Details